乳腺癌雄激素受体与p16蛋白表达的临床意义  

The Expression of Androgen Receptor,p16 Protein in Breast Carcinoma and its Clinical Significance

作　　者：沈敬华[1] 何洛文[1] 万文徽[1] 高学硕[1] 马泓[1] 

机构地区：[1]北京市肿瘤防治研究所,北京100034

出　　处：《中国肿瘤》2001年第4期242-243,共2页China Cancer

摘　　要：目的]探讨雄激素受体、p16蛋白在乳腺癌中的表达情况及其临床价值。[方法]应用SP免疫组织化学方法对61例乳腺癌组织中雄激素受体及CDKNI抑癌基因p16蛋白表达进行研究。[结果]雄激素受体阳性表达与乳腺癌的淋巴结转移呈负相关(P<0 05) ,与5年生存期呈正相关(P<0 005),与 p16蛋白表达呈正相关(P<0 005)。[结论]雄激素受体与p16蛋白表达可结合起来作为乳腺癌的一个生物学指标及预后的判断指标 。To explore the expression of androgen receptor and p16 protein in breast carcinoma,and its clinical significance.The expression of androgen receptor and p16 protein was examined by means of SP immunohistochemical technique in 61 cases with breast cancer proved by pathology.The expression of androgen receptor (AR) revealed negative correlation with lymph node metastasis (P<0 05),and positive correlation with 5-year survival (P<0 005) in patients with breast cancer.The expression of AR was positive correlation with p16 protein in breast cancer (P<0 005).[Conclusion] Combination of AR and p16 protein should determined as a biological factor and prognostic factor for breast cancer,which can provide the theoretial warranty for hormonal therapy.

关 键 词：乳腺肿瘤 雄激素受体 p16蛋白质 单克隆抗体 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]